Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark P Lythgoe

Showing results (1-10 of 65) with videos related to

Pageof 7
Sort By:
British Journal of Pharmacology|September 27, 2022
No new 'mabs' in medicine-New nomenclature for monoclonal antibodiesMark P Lythgoe
Trends in Pharmacological Sciences|April 16, 2020
Ongoing Clinical Trials for the Management of the COVID-19 PandemicMark P Lythgoe, Paul Middleton
Journal of Cancer Policy|May 13, 2022
The last word to new FDA draft guidance for cancer clinical trial eligibility criteria for patients with incurable cancerMark P Lythgoe, Vinay Prasad
European Journal of Cancer (Oxford, England : 1990)|May 9, 2022
Approved anti-PD-1 monoclonal antibodies in China: A bridge too far for US approvalMark P Lythgoe, Richard Sullivan
The Lancet. Oncology|July 28, 2022
Project Orbis: the UK experience after 1 yearMark P Lythgoe, Richard Sullivan
British Journal of Cancer|June 23, 2022
Repositioning canakinumab for non-small cell lung cancer-important lessons for drug repurposing in oncologyMark P Lythgoe, Vinay Prasad
Nature Reviews. Clinical Oncology|September 18, 2021
The FDA's latest move to expand eligibility for oncology trials - a double-edged sword?Mark P Lythgoe, Vinay Prasad
European Journal of Cancer (Oxford, England : 1990)|September 6, 2021
How the US Food and Drug Administration's approval of aducanumab for Alzheimer's disease has implication for oncology and beyondMark P Lythgoe, Vinay Prasad
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|April 30, 2016
Good practice in shared care for inflammatory arthritisMark P Lythgoe, Sonya Abraham
Lancet (London, England)|July 1, 2023
Outsourcing UK regulatory decisions-a double-edged sword?Mark P Lythgoe, Richard Sullivan
Pageof 7

Showing results (1-10 of 65) with videos related to

Sort By:
Pageof 7
British Journal of Pharmacology|September 27, 2022
No new 'mabs' in medicine-New nomenclature for monoclonal antibodiesMark P Lythgoe
Trends in Pharmacological Sciences|April 16, 2020
Ongoing Clinical Trials for the Management of the COVID-19 PandemicMark P Lythgoe, Paul Middleton
Journal of Cancer Policy|May 13, 2022
The last word to new FDA draft guidance for cancer clinical trial eligibility criteria for patients with incurable cancerMark P Lythgoe, Vinay Prasad
European Journal of Cancer (Oxford, England : 1990)|May 9, 2022
Approved anti-PD-1 monoclonal antibodies in China: A bridge too far for US approvalMark P Lythgoe, Richard Sullivan
The Lancet. Oncology|July 28, 2022
Project Orbis: the UK experience after 1 yearMark P Lythgoe, Richard Sullivan
British Journal of Cancer|June 23, 2022
Repositioning canakinumab for non-small cell lung cancer-important lessons for drug repurposing in oncologyMark P Lythgoe, Vinay Prasad
Nature Reviews. Clinical Oncology|September 18, 2021
The FDA's latest move to expand eligibility for oncology trials - a double-edged sword?Mark P Lythgoe, Vinay Prasad
European Journal of Cancer (Oxford, England : 1990)|September 6, 2021
How the US Food and Drug Administration's approval of aducanumab for Alzheimer's disease has implication for oncology and beyondMark P Lythgoe, Vinay Prasad
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|April 30, 2016
Good practice in shared care for inflammatory arthritisMark P Lythgoe, Sonya Abraham
Lancet (London, England)|July 1, 2023
Outsourcing UK regulatory decisions-a double-edged sword?Mark P Lythgoe, Richard Sullivan
Pageof 7